[1] Kolterman O G, Kim D D, Shen L, et al. Pharmacokinetics, pharmacodynamics and safety of exenatide in patients with type 2 diabetes mellitus. Am Health Syst Pharm, 2005, 62 : 173-181.
[2] Kwon D Y, Kim Y S, Ahn I S,et al. Exendin-4 potentiates insulinotropic action partly via increasing beta-cell proliferation and neogenesis and decreasing apoptosis in association with the attenuation of endoplasmic reticulum stress in islets of diabetic rats. J Pharmacol Sci, 2009, 111 (4) : 361-371.
[3] Derosa G, Maffioli P, Salvadeo S A T, et al. Exenatide versus glibenclamide in patients with diabetes. Diabetes Technology and Therapeutics, 2010, 12 (3) : 233-240.
[4] Bunck M C, Diamant M, Corner A, et al. One-year treatment with Exenatide improves cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trial. Diabetes Care, 2009, 32 : 762-768.
[5] 孙玉昆,伍登熙,朱志勇,等.促胰岛素分泌肽衍生物. 中国,1363559,2002-08-14. Sun Y K, Wu D X, Zhu Z Y, et al. Insulinotropic hormone secretion peptide derivative. China, 1363559, 2002-08-14.
[6] Kent S B, Merrifield R B. Chemical mechanism to account for artifactual formation of shortened peptides with free alpha-amino groups in solid phase peptide synthesis. Int J Pept Res,1983, 22(1):57-65.
[7] Louis A C, Grace Y H. 9-Fluoenylmethoxycarbonyl amino-protecting group. J Org Chem, 1972,37(22):3404-3409.
[8] 周国华, 罗国安, 朱敏生. 基体辅助激光解吸质谱法在生物大分子质量研究中的应用. 药学学报, 1998,33(4):290-295. Zhou G H, Luo G A, Zhu M S.Acta Pharmaceutica Sinica, 1998,33(4):290-295. |